Multidisciplinary Approaches to the Management of Atopic Dermatitis - Episode 9
Expectations for Efficacy and Duration of Response With Systemic Atopic Dermatitis Treatments
Published on:
Panelists discuss treatment expectations for newer systemic agents, highlighting data on efficacy onset and persistence, including rapid improvement in pruritus with dupilumab by week 2 (SOLO trials), early Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI)-75 improvement with lebrikizumab by week 2 to 4 (ADvocate trials), and EASI-75 improvement with tralokinumab by week 4 (ECZTRA 6 trial), emphasizing the importance of setting realistic expectations with patients and caregivers regarding the onset of action and duration of treatment.
Video content above is prompted by the following:
- Let’s shift now to treatment expectations. What are the data about efficacy onset and persistence when considering these newer systemic agents?
- How do you set expectations with patients starting on systemic treatment and their caregivers in terms of onset of action and duration of treatment?
- Dupilumab in the SOLO trials showed improvement on Peak Pruritus Numerical Rating Scale score at week 2 (in adults).
- Lebrikizumab in the ADvocate trials showed some IGA improvement at week 4 and some EASI-75 improvement at week 2.
- Tralokinumab in the ECZTRA 6 trial showed some EASI-75 improvement at 4 weeks (in adolescents).
